Companies: 10,795·Total market cap: $144.5T
Biofrontera Inc.

Biofrontera Inc.

BFRINASDAQHealthcare● Active
$0.93
$-0.01(-0.53%)
Market Cap$11907110
P/E Ratio
52W High$1.19
52W Low$0.555

Biofrontera Inc. (BFRI) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

bfri · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Biofrontera Inc. (BFRI) measures how much investors pay for each dollar of the company's trailing earnings. BFRI's current PE ratio of N/A is calculated by dividing its stock price of $0.93 by its TTM earnings per share of -$0.95.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
4.89x
FY2027 est. EPS $0.19
Based on 1 analyst
EPS (TTM)
-$0.95
TTM · diluted EPS
PEG Ratio
-0.03
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Biofrontera Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Biofrontera Inc.
Biofrontera Inc.You
BFRI
$12MN/A-$0.95
Aytu BioPharma, Inc.
Aytu BioPharma, Inc.
AYTU
$19MN/A-$2.16
Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc.
COCP
$10MN/A-$0.78
Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc.
DWTX
$3MN/A-$4.17
Evogene Ltd.
Evogene Ltd.
EVGN
$5MN/A-$1.08
Gelteq Limited Ordinary Shares
Gelteq Limited Ordinary Shares
GELS
$4MN/A$0.00
Imunon, Inc.
Imunon, Inc.
IMNN
$5MN/A-$6.83

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-1.04
2024-12-31
FY2024
$-3.22
2023-12-31
FY2023
$-13.02
2022-12-31
FY2022
$-0.61
2021-12-31
FY2021
$-44.10
2020-12-31
FY2020
$-18.94
2019-12-31
FY2019
$-18.09

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Biofrontera Inc. (BFRI) measures how much investors pay for each dollar of the company's trailing earnings. BFRI's current PE ratio of N/A is calculated by dividing its stock price of $0.93 by its TTM earnings per share of -$0.95.

PE Ratio = Stock Price ÷ EPS (TTM)
= $0.93 ÷ -$0.95 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

BFRI pe ratio · 6 questions

BFRI's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.93 and TTM EPS of -$0.95. Data sourced from Financial Modeling Prep via BFRI's SEC 10-K and 10-Q filings.

BFRI PE ratioWhat is BFRI PE ratioCurrent PE ratio of BFRIBFRI PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Biofrontera Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08